ESMO 2021 Kidney Cancer - Results from #20

Viewing 21-29 of 29 articles

ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial

ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial (Meeturo 2)

ESMO 2021: Cabozantinib-Nivolumab Versus Nivolumab-Cabozantinib in Patients With Metastatic Clear Cell RCC Following One Prior VEGFR TKI: The CABIR Multicenter Matching-Adjusted Study

ESMO 2021: Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update

ESMO 2021: Randomized, Open-Label, 3-Arm Phase 3 Study Comparing MK-1308A + Lenvatinib and Pembrolizumab + Belzutifan + Lenvatinib versus Pembrolizumab + Lenvatinib as First-line Treatment for Advanced Clear Cell RCC

ESMO 2021: Conditional Survival and 5-Year Follow-Up in CheckMate 214: First-Line Nivolumab + Ipilimumab Versus Sunitinib in Advanced RCC

ESMO 2021: CABOPRE: A Phase II Study of Cabozantinib (Cabo) Prior Cytoreductive Nephrectomy (CN) in Metastatic Renal Cell Carcinoma (mRCC)

ESMO 2021: Final Results on Efficacy and Patient Reported Outcomes (PRO) of a Randomized Phase II Trial Investigating Nivolumab Switch-Maintenance After TKI Induction in Metastatic Clear Cell Renal Cell Carcinoma (mRCC) Patients (NIVOSWITCH)

ESMO 2021: Tissue-based biomarker in renal cancer: Opportunities and challenges

1
2